Login
Home
Charts
Search
Watchlist
Products

Glaxosmithkline Pharmaceuticals Ltd

GLAXO·NSE
₹2,870.00+0.25%Tue, 22 Sept '26 15:22
Industry:Pharma - MNC bulk Drugs
Indices:

Glaxosmithkline Pharmaceuticals Ltd

GLAXO
NSE
₹2,870.00
+0.25%
|Tue, 22 Sept '26 15:22
SOICxStockScans Reports
Industry
Pharma - MNC bulk Drugs
Indices
View
Financials
Documents
Shareholdings
Corporate Actions
Segments
Quick Ratios
Quarterly Results
Profit & Loss
Balance Sheet
Cash Flow
Ratios
Peer Comparison
Financials
Documents
Shareholdings
Corporate Actions
Segments
Quick Ratios
Quarterly Results
Profit & Loss
Balance Sheet
Cash Flow
Ratios
Peer Comparison
6M
Price
Charts
Documents

Quick Ratios

Edit Ratios
Mkt Cap
Market Capitalization
₹48,636Cr
Close
Close Price
₹2,871.00
Industry
Industry
Pharma - MNC bulk Drugs
PE
Price To Earnings
46.30
PS
Price To Sales
12.30
Revenue
Revenue
₹3,955Cr
Rev Gr TTM
Revenue Growth TTM
5.75%
PAT Gr TTM
PAT Growth TTM
12.41%

Quarterly Results

Consolidated
Standalone
Numbers
Percentage
QuarterSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
9578059308151,0119499748059801,041995938
Growth YoY
Revenue Growth YoY%
4.40.418.17.05.617.94.8-1.2-3.09.72.116.6
Expenses
ExpensesCr
668587673584689658641554644670644643
Operating Profit
Operating ProfitCr
289218257231322292333251336371351296
OPM
OPM%
30.327.127.728.331.830.834.231.234.335.735.331.5
Other Income
Other IncomeCr
28-13532363935414436503644
Interest Expense
Interest ExpenseCr
001000101111
Depreciation
DepreciationCr
181718161719151617201316
PBT
PBTCr
29965271249344308359279354400373322
Tax
TaxCr
8220766791789674971049585
PAT
PATCr
21846194182253230263205257296278237
Growth YoY
PAT Growth YoY%
12.4-72.245.837.916.1402.835.212.42.028.65.715.7
NPM
NPM%
22.75.720.922.425.024.227.025.526.328.427.925.3
EPS
EPS₹
12.89.911.410.814.713.615.512.115.116.516.414.0
QuarterSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
9578059308151,0119499748059801,041995938
Growth YoY
Revenue Growth YoY%
4.40.418.17.05.617.94.8-1.2-3.09.72.116.6
Expenses
ExpensesCr
668587673584689658641554644670644643
Operating Profit
Operating ProfitCr
289218257231322292333251336371351296
OPM
OPM%
30.327.127.728.331.830.834.231.234.335.735.331.5
Other Income
Other IncomeCr
28-13532363935414436503644
Interest Expense
Interest ExpenseCr
001000101111
Depreciation
DepreciationCr
181718161719151617201316
PBT
PBTCr
29965271249344308359279354400373322
Tax
TaxCr
8220766791789674971049585
PAT
PATCr
21846194182253230263205257296278237
Growth YoY
PAT Growth YoY%
12.4-72.245.837.916.1402.835.212.42.028.65.715.7
NPM
NPM%
22.75.720.922.425.024.227.025.526.328.427.925.3
EPS
EPS₹
12.89.911.410.814.713.615.512.115.116.516.414.0

Profit & Loss

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
2,8382,9082,8713,1283,2242,9263,2783,2523,4543,7493,8223,955
Growth
Revenue Growth%
-14.12.5-1.38.93.1-9.312.1-0.86.28.61.95.8
Expenses
ExpensesCr
2,3602,4892,3662,5272,5672,3272,5162,4472,5452,5722,5122,601
Operating Profit
Operating ProfitCr
4784195066016575987628049091,1771,3091,354
OPM
OPM%
16.914.417.619.220.420.423.224.726.331.434.334.2
Other Income
Other IncomeCr
12511972131-262-6287100-21151166166
Interest Expense
Interest ExpenseCr
000164222133
Depreciation
DepreciationCr
252638498379686670676667
PBT
PBTCr
5785115406833064547798368161,2601,4061,449
Tax
TaxCr
202174189237213167398229226332370381
PAT
PATCr
376337351445932873816085909281,0361,068
Growth
PAT Growth%
-21.1-10.54.127.0-79.1208.232.559.6-2.957.211.712.4
NPM
NPM%
13.311.612.214.22.99.811.618.717.124.727.127.0
EPS
EPS₹
22.219.920.726.35.521.1100.036.141.154.560.162.0
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
2,8382,9082,8713,1283,2242,9263,2783,2523,4543,7493,8223,955
Growth
Revenue Growth%
-14.12.5-1.38.93.1-9.312.1-0.86.28.61.95.8
Expenses
ExpensesCr
2,3602,4892,3662,5272,5672,3272,5162,4472,5452,5722,5122,601
Operating Profit
Operating ProfitCr
4784195066016575987628049091,1771,3091,354
OPM
OPM%
16.914.417.619.220.420.423.224.726.331.434.334.2
Other Income
Other IncomeCr
12511972131-262-6287100-21151166166
Interest Expense
Interest ExpenseCr
000164222133
Depreciation
DepreciationCr
252638498379686670676667
PBT
PBTCr
5785115406833064547798368161,2601,4061,449
Tax
TaxCr
202174189237213167398229226332370381
PAT
PATCr
376337351445932873816085909281,0361,068
Growth
PAT Growth%
-21.1-10.54.127.0-79.1208.232.559.6-2.957.211.712.4
NPM
NPM%
13.311.612.214.22.99.811.618.717.124.727.127.0
EPS
EPS₹
22.219.920.726.35.521.1100.036.141.154.560.162.0

Balance Sheet

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
858585169169169169169169169169
Reserves
ReservesCr
2,0991,9221,9731,9701,6511,3092,4941,5721,6081,7822,098
Current Liabilities
Current LiabilitiesCr
5797201,6001,4541,0241,3551,6981,3261,5251,9051,779
Non Current Liabilities
Non Current LiabilitiesCr
292277290317291282272259254252277
Total Liabilities
Total LiabilitiesCr
3,0553,0043,9473,9113,1363,1154,6333,3273,5574,1084,324
Current Assets
Current AssetsCr
2,1741,6742,1862,0091,7752,2033,7082,4942,7983,4103,606
Non Current Assets
Non Current AssetsCr
8811,3301,7611,9021,361912925832758698718
Total Assets
Total AssetsCr
3,0553,0043,9473,9113,1363,1154,6333,3273,5574,1084,324
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
858585169169169169169169169169
Reserves
ReservesCr
2,0991,9221,9731,9701,6511,3092,4941,5721,6081,7822,098
Current Liabilities
Current LiabilitiesCr
5797201,6001,4541,0241,3551,6981,3261,5251,9051,779
Non Current Liabilities
Non Current LiabilitiesCr
292277290317291282272259254252277
Total Liabilities
Total LiabilitiesCr
3,0553,0043,9473,9113,1363,1154,6333,3273,5574,1084,324
Current Assets
Current AssetsCr
2,1741,6742,1862,0091,7752,2033,7082,4942,7983,4103,606
Non Current Assets
Non Current AssetsCr
8811,3301,7611,9021,361912925832758698718
Total Assets
Total AssetsCr
3,0553,0043,9473,9113,1363,1154,6333,3273,5574,1084,324

Cash Flow

Consolidated
Standalone
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
1392344733994915788114845821,290903
Investing Cash Flow
Investing Cash FlowCr
499301-104-143-57418-4068089-46397
Financing Cash Flow
Financing Cash FlowCr
-638-511-307-358-428-696-524-1,543-562-769-737
Net Cash Flow
Net Cash FlowCr
02462-1026300-119-25129475563
Free Cash Flow
Free Cash FlowCr
-69-246391563365368104515731,273870
CFO To PAT
CFO To PAT%
36.969.6134.889.7526.3201.2212.979.798.7139.187.2
CFO To EBITDA
CFO To EBITDA%
29.055.993.566.574.696.6106.460.264.0109.669.0
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
1392344733994915788114845821,290903
Investing Cash Flow
Investing Cash FlowCr
499301-104-143-57418-4068089-46397
Financing Cash Flow
Financing Cash FlowCr
-638-511-307-358-428-696-524-1,543-562-769-737
Net Cash Flow
Net Cash FlowCr
02462-1026300-119-25129475563
Free Cash Flow
Free Cash FlowCr
-69-246391563365368104515731,273870
CFO To PAT
CFO To PAT%
36.969.6134.889.7526.3201.2212.979.798.7139.187.2
CFO To EBITDA
CFO To EBITDA%
29.055.993.566.574.696.6106.460.264.0109.669.0

Ratios

Consolidated
Standalone
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
32,19223,16717,66322,02021,09524,40128,17122,43232,91748,74338,68248,636
Price To Earnings
Price To Earnings
120.068.850.449.4226.468.116.636.755.852.537.346.3
Price To Sales
Price To Sales
11.38.06.27.06.58.38.66.99.513.010.112.3
Price To Book
Price To Book
14.811.58.610.311.616.510.612.918.525.017.121.4
EV To EBITDA
EV To EBITDA
64.453.132.434.730.438.933.726.535.140.228.534.5
Profitability Ratios
Profitability Ratios
GPM
GPM%
48.247.352.052.055.052.454.156.557.259.061.261.2
OPM
OPM%
16.914.417.619.220.420.423.224.726.331.434.334.2
NPM
NPM%
13.311.612.214.22.99.811.618.717.124.727.127.0
ROCE
ROCE%
26.525.526.331.917.130.229.147.745.564.361.261.2
ROE
ROE%
17.216.817.120.85.119.414.334.933.247.545.745.7
ROA
ROA%
12.311.28.911.43.09.28.218.316.622.624.024.0
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
32,19223,16717,66322,02021,09524,40128,17122,43232,91748,74338,68248,636
Price To Earnings
Price To Earnings
120.068.850.449.4226.468.116.636.755.852.537.346.3
Price To Sales
Price To Sales
11.38.06.27.06.58.38.66.99.513.010.112.3
Price To Book
Price To Book
14.811.58.610.311.616.510.612.918.525.017.121.4
EV To EBITDA
EV To EBITDA
64.453.132.434.730.438.933.726.535.140.228.534.5
Profitability Ratios
Profitability Ratios
GPM
GPM%
48.247.352.052.055.052.454.156.557.259.061.261.2
OPM
OPM%
16.914.417.619.220.420.423.224.726.331.434.334.2
NPM
NPM%
13.311.612.214.22.99.811.618.717.124.727.127.0
ROCE
ROCE%
26.525.526.331.917.130.229.147.745.564.361.261.2
ROE
ROE%
17.216.817.120.85.119.414.334.933.247.545.745.7
ROA
ROA%
12.311.28.911.43.09.28.218.316.622.624.024.0
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios

Documents — Glaxosmithkline Pharmaceuticals Ltd

  • Q1 FY2027 Earnings Call Transcript (Jun 2026, PDF): https://www.stockscans.in/document/bd7ciihn1l2nxs7a74uih9i9.pdf
  • Q4 FY2026 Earnings Call Transcript (Mar 2026, PDF): https://www.stockscans.in/document/4yjf9cgw5hc2dgajyh0qd5wc.pdf
  • Q3 FY2026 Earnings Call Transcript (Dec 2025, PDF): https://www.stockscans.in/document/qshy14u0fs89hmu9s95eikgn.pdf
  • Q2 FY2026 Earnings Call Transcript (Sep 2025, PDF): https://www.stockscans.in/document/m8owivvi6072v422tnuabqj3.pdf
  • Q1 FY2026 Earnings Call Transcript (Jun 2025, PDF): https://www.stockscans.in/document/m4dz32u8owcd7oupteb44dng.pdf
  • Q4 FY2025 Earnings Call Transcript (Mar 2025, PDF): https://www.stockscans.in/document/93425ou5au1wydk8mqi6xb44.pdf
  • Q3 FY2025 Earnings Call Transcript (Dec 2024, PDF): https://www.stockscans.in/document/zv1lvayi1mrh0ifscw5aegov.pdf
  • Q1 FY2027 Quarterly Result (Jun 2026, PDF): https://www.stockscans.in/document/ba027g6vqv1d5b6w0vlyka15.pdf
  • Q4 FY2026 Quarterly Result (Mar 2026, PDF): https://www.stockscans.in/document/zzkkz40v7jgt5jnuw4u9ka1i.pdf
  • Q3 FY2026 Quarterly Result (Dec 2025, PDF): https://www.stockscans.in/document/0wyzbaf6gk6mha1kq0b1f5ps.pdf
  • Q2 FY2026 Quarterly Result (Sep 2025, PDF): https://www.stockscans.in/document/cf1h546684lt0h7gsan1m6ek.pdf
  • Q1 FY2026 Quarterly Result (Jun 2025, PDF): https://www.stockscans.in/document/9ux78i2cdd4tzgz2w9qybhrj.pdf
  • Q4 FY2025 Quarterly Result (Mar 2025, PDF): https://www.stockscans.in/document/rtb4tu1lmednnbz6xtm9cdq2.pdf
  • Q3 FY2025 Quarterly Result (Dec 2024, PDF): https://www.stockscans.in/document/vf6f0qvtcdpqhvclxueyknpr.pdf
  • Q2 FY2025 Quarterly Result (Sep 2024, PDF): https://www.stockscans.in/document/dvrdgouzq2q0iyuw8gbbbbks.pdf
  • Q4 FY2026 Investor Presentation (Mar 2026, PDF): https://www.stockscans.in/document/174va8l17vqth7a0r5lfe63s.pdf
  • Q2 FY2026 Investor Presentation (Sep 2025, PDF): https://www.stockscans.in/document/blqd5lid0fp4nxh56a5hsjjf.pdf
  • Q1 FY2026 Investor Presentation (Jun 2025, PDF): https://www.stockscans.in/document/z2u0fc19fuht5enp0dnlrgd7.pdf
  • Q4 FY2025 Investor Presentation (Mar 2025, PDF): https://www.stockscans.in/document/7moh4qffao3zxeijoplhuzzu.pdf
  • FY2026 Annual Report (PDF): https://www.stockscans.in/document/gm45jo69rqu8exqbf9ltqvp8.pdf
  • FY2025 Annual Report (PDF): https://www.stockscans.in/document/nzoprzilh2wx5ibgd5j58d13.pdf
  • FY2024 Annual Report (PDF): https://www.stockscans.in/document/8345jwnq7sumqpyquhcutkek.pdf
  • FY2023 Annual Report (PDF): https://www.stockscans.in/document/vnwdzdr86ewes2cd2o8htg1p.pdf
  • FY2022 Annual Report (PDF): https://www.stockscans.in/document/8uk2uajway5ck09gbnhmb5nv.pdf
  • FY2021 Annual Report (PDF): https://www.stockscans.in/document/7hv8pg7hvc0d3wup896is34b.pdf
  • FY2020 Annual Report (PDF): https://www.stockscans.in/document/rfg7ffaanvx6s8hq4l2wuvti.pdf

Concall Transcript Summaries — Glaxosmithkline Pharmaceuticals Ltd

  • Q1 FY2027 Concall Transcript Summary (Jun 2026): https://www.stockscans.in/company/NSE%3AGLAXO/transcript-notes/202606/bd7ciihn1l2nxs7a74uih9i9.pdf
  • Q4 FY2026 Concall Transcript Summary (Mar 2026): https://www.stockscans.in/company/NSE%3AGLAXO/transcript-notes/202603/4yjf9cgw5hc2dgajyh0qd5wc.pdf
  • Q3 FY2026 Concall Transcript Summary (Dec 2025): https://www.stockscans.in/company/NSE%3AGLAXO/transcript-notes/202512/qshy14u0fs89hmu9s95eikgn.pdf
  • Q2 FY2026 Concall Transcript Summary (Sep 2025): https://www.stockscans.in/company/NSE%3AGLAXO/transcript-notes/202509/m8owivvi6072v422tnuabqj3.pdf
  • Q1 FY2026 Concall Transcript Summary (Jun 2025): https://www.stockscans.in/company/NSE%3AGLAXO/transcript-notes/202506/m4dz32u8owcd7oupteb44dng.pdf
  • Q4 FY2025 Concall Transcript Summary (Mar 2025): https://www.stockscans.in/company/NSE%3AGLAXO/transcript-notes/202503/93425ou5au1wydk8mqi6xb44.pdf
  • Q3 FY2025 Concall Transcript Summary (Dec 2024): https://www.stockscans.in/company/NSE%3AGLAXO/transcript-notes/202412/zv1lvayi1mrh0ifscw5aegov.pdf

Simplify stock analysis with powerful tools and clear insights for confident, data-driven decisions.

support@stockscans.in
© StockScans by SOIC Technologies Pvt Ltd
349 A, Lodhi Road, Punjabi Bazar, New DelhiData provided by CMOTS Internet Technologies